Released in Cape Town at the IAS conference, this year's report shows that in 2008 US$868 million was spent on vaccines, US$244 million on microbicides, and US$81 million on other new prevention options such as pre-exposure prophylaxis using antiretroviral drugs (PrEP), and the rollout of medical male circumcision.
These amounts reflect a 10% decline in funding for vaccines and an 8% increase in microbicides research funding between 2007 and 2008.
The year 2008 saw a range of funding changes from the previous year, both within and among different technologies. The overall trend for almost a decade, though, has been of increasing investment for all experimental biomedical prevention strategies. However, recent changes in scientific priorities, competing global health needs and the downturn in the economy could impact future funding decision-making. To ensure new HIV prevention options are developed and implemented, it will be critical that HIV prevention research funding is sustained.
Previous editions are available to download on the AVAC Publications page.